This product includes the webinar and CME/CMLE credit.
Following a brief overview on the difficulties encountered in the definition of the epidemiology, classification, diagnosis, prognosis, and therapy of peripheral T/NK-cell lymphomas, nodal peripheral T-cell lymphomas (PTCLs) will be discussed in detail. These neoplasms account for more than 60% of tumours stemming from peripheral T-lymphocytes. In the Revised WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, they correspond to 4 entities: PTCL, not otherwise specified (NOS), PTCLs related to follicular helper T-lymphocytes (FTH), ALK+ anaplastic large cell lymphoma (ALCL), and ALK- ALCL. Tumour related to TFH cells represent a new category, including angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma and neoplasms lacking the morphologic characteristics of the previous two subtypes but also stemming from TFH-elements. The latter group was in the past included among PTCLs/NOS. ALK- ALCL was promoted from provisional to accepted entity because of emerging molecular evidences. In addition, the new provisional category of breast implant-associated ALCL was included. Most of the changes introduced in the Revised WHO Classification by comparison with the 2008 fourth edition are due to the extensive application of molecular techniques, including gene expression profiling and next generation sequencing. All the changes will be highlighted and discussed.
A collaborative educational event presented by Association for Molecular Pathology (AMP) and Society for Hematopathology (SH).
Speaker: Stefano A. Pileri, MD
Host: Jennifer Dunlap, MD
Duration: 1 hr
Level of Instruction: Intermediate
Last day to purchase course and claim credit: January 18, 2021
Maximum CME/CMLE credit available: 1.0
How to claim credit: To earn CME/CMLE credit, all learners must watch the webinar and then complete the online survey. To access the online survey, click "Submit credit" on the course homepage, or click on "My Credit" on the menu to the left.
AMA PRA Category 1 Credit(s)™
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.
The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.
* You may not submit SAMs and CME/CMLE credit for the same content.
You may also be interested in:
Note: Join the AMP Family to purchase this content for a deep discount!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
January 18, 2018
American Medical Association
Continuing Medical Education: 1.00
American Society for Clinical Pathology
Pileri Presentation (+CME)
AMP Regular Member: $5.00
AMP Technologist Member: $5.00
AMP Associate Member: $5.00
Non-member Price: $205.00